Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
Ocugen's Chairman, CEO, and Co-founder, Dr. Shankar Musunuri, is set to speak at a U.S.-India biotechnology cooperation workshop in New Delhi from September 9-11, 2024. The event, titled 'U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks,' is part of the U.S.-India Initiative on Critical and Emerging Technology.
Dr. Musunuri will participate in a panel discussion on 'Persistent Challenges: Right-Sizing Regulations and Setting Standards Beyond the Biomedical Sphere' on September 10. The workshop series, organized by the U.S. National Academies of Sciences, Engineering, and Medicine and the Indian National Science Academy, aims to identify opportunities for collaboration in biotechnology between the two countries.
Ocugen, a NASDAQ-listed biotechnology company (OCGN), focuses on gene and cell therapies, and vaccines. With its new site in Hyderabad, India, Ocugen is actively contributing to strengthening U.S.-India biotechnology cooperation.
Il presidente, CEO e cofondatore di Ocugen, Dr. Shankar Musunuri, interverrà a un seminario sulla cooperazione biotecnologica tra Stati Uniti e India a Nuova Delhi dal 9 all'11 settembre 2024. L'evento, intitolato 'Cooperazione Biotecnologica Stati Uniti-India: Realizzare Benefici, Ridurre Rischi', fa parte dell'Iniziativa Stati Uniti-India su Tecnologie Critiche ed Emergenti.
Il Dr. Musunuri parteciperà a una discussione di panel su 'Sfide Persistenti: Dimensionare Adeguatamente le Regolazioni e Stabilire Standard Oltre la Sfera Biomedica' il 10 settembre. La serie di seminari, organizzata dalle Accademie Nazionali di Scienze, Ingegneria e Medicina degli Stati Uniti e dall'Accademia Nazionale delle Scienze dell'India, mira a individuare opportunità di collaborazione nella biotecnologia tra i due paesi.
Ocugen, una società biotecnologica quotata al NASDAQ (OCGN), si concentra su terapie geniche e cellulari, e vaccini. Con il suo nuovo sito a Hyderabad, India, Ocugen sta contribuendo attivamente a rafforzare la cooperazione biotecnologica tra Stati Uniti e India.
El presidente, CEO y cofundador de Ocugen, Dr. Shankar Musunuri, está programado para hablar en un taller de cooperación biotecnológica entre Estados Unidos y India en Nueva Delhi del 9 al 11 de septiembre de 2024. El evento, titulado 'Cooperación Biotecnológica EE.UU.-India: Realizando Beneficios, Reduciendo Riesgos', forma parte de la Iniciativa EE.UU.-India sobre Tecnologías Críticas y Emergentes.
El Dr. Musunuri participará en una mesa redonda sobre 'Desafíos Persistentes: Dimensiones Adecuadas de Regulaciones y Establecimiento de Normas Más Allá del Ámbito Biomédico' el 10 de septiembre. La serie de talleres, organizada por las Academias Nacionales de Ciencias, Ingeniería y Medicina de EE.UU. y la Academia Nacional de Ciencias de India, tiene como objetivo identificar oportunidades de colaboración en biotecnología entre los dos países.
Ocugen, una empresa biotecnológica cotizada en NASDAQ (OCGN), se centra en terapias génicas y celulares, así como en vacunas. Con su nuevo sitio en Hyderabad, India, Ocugen está contribuyendo activamente a fortalecer la cooperación biotecnológica entre Estados Unidos e India.
Ocugen의 회장, CEO 및 공동 창립자인 Dr. Shankar Musunuri가 2024년 9월 9일부터 11일 사이에 뉴델리에서 열리는 미국-인도 생명공학 협력 워크숍에서 연설할 예정입니다. '미국-인도 생명공학 협력: 이점 실현, 위험 줄이기'라는 제목의 이 행사는 미국-인도의 중요한 및 신기술에 대한 이니셔티브의 일환으로 진행됩니다.
Musunuri 박사는 9월 10일 '지속적인 도전 과제: 생물 의학 분야를 넘어서 규제 적정화 및 기준 설정'이라는 주제로 패널 토론에 참여합니다. 미국 국립 과학, 공학 및 의학 아카데미와 인도 국립 과학 아카데미가 주관하는 이번 워크숍 시리즈는 양국 간 생명공학 협력의 기회를 찾는 것을 목표로 하고 있습니다.
Ocugen은 NASDAQ에 상장된 생명공학 회사(OCGN)로, 유전자 및 세포 치료제, 백신에 집중하고 있습니다. 인도 하이데라바드에 새로 설립된 사이트를 통해 Ocugen은 미국-인도 생명공학 협력을 강화하는 데 적극적으로 기여하고 있습니다.
Le président, PDG et cofondateur d'Ocugen, Dr. Shankar Musunuri, doit s'exprimer lors d'un atelier de coopération biotechnologique États-Unis-Inde à New Delhi du 9 au 11 septembre 2024. L'événement, intitulé 'Coopération biotechnologique États-Unis-Inde : Réaliser des avantages, réduire les risques', fait partie de l'Initiative États-Unis-Inde sur les technologies critiques et émergentes.
Le Dr Musunuri participera à une table ronde sur 'Défis persistants : Dimensionnement approprié des règlements et définition de normes au-delà de la sphère biomédicale' le 10 septembre. La série d'ateliers, organisée par les Académies nationales des sciences, de l'ingénierie et de la médecine des États-Unis et l'Académie nationale des sciences de l'Inde, vise à identifier des opportunités de collaboration en biotechnologie entre les deux pays.
Ocugen, une entreprise de biotechnologie cotée au NASDAQ (OCGN), se concentre sur les thérapies géniques et cellulaires, ainsi que sur les vaccins. Avec son nouveau site à Hyderabad, en Inde, Ocugen contribue activement au renforcement de la coopération biotechnologique entre les États-Unis et l'Inde.
Der Vorsitzende, CEO und Mitbegründer von Ocugen, Dr. Shankar Musunuri, wird vom 9. bis 11. September 2024 auf einem Workshop zur biotechnologischen Zusammenarbeit zwischen den USA und Indien in Neu-Delhi sprechen. Die Veranstaltung mit dem Titel 'Biotechnologische Zusammenarbeit zwischen den USA und Indien: Nutzen realisieren, Risiken reduzieren' ist Teil der US-Indien-Initiative für kritische und aufkommende Technologien.
Dr. Musunuri wird am 10. September an einer Podiumsdiskussion mit dem Thema 'Hartnäckige Herausforderungen: Angemessene Regulierung und Festlegung von Standards über den biomedizinischen Bereich hinaus' teilnehmen. Die Workshop-Reihe, die von den US National Academies of Sciences, Engineering, and Medicine und der Indian National Science Academy organisiert wird, zielt darauf ab, Möglichkeiten zur Zusammenarbeit im Bereich Biotechnologie zwischen den beiden Ländern zu identifizieren.
Ocugen, ein an der NASDAQ gelistetes Biotechnologieunternehmen (OCGN), konzentriert sich auf Gen- und Zelltherapien sowie Impfstoffe. Mit seinem neuen Standort in Hyderabad, Indien, leistet Ocugen aktiv einen Beitrag zur Stärkung der biotechnologischen Zusammenarbeit zwischen den USA und Indien.
- None.
- None.
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, “U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks.” This two-day event will take place from September 9-11, 2024 in New Delhi, India.
“It is an honor to join the impressive group of thought leaders in this groundbreaking forum,” said Dr. Musunuri. “There are endless opportunities to leverage the best the U.S. and India have to offer across all facets of biotechnology. With the addition of our site in Hyderabad, India, Ocugen is doing its part to strengthen collaboration.”
The U.S. National Academies of Sciences, Engineering, and Medicine (NASEM), together with the Indian National Science Academy (INSA), are convening experts from both countries for two virtual workshops and one in-person workshop. The primary goal of this workshop series is to identify short-, medium-, and long-term opportunities for U.S.- India biotechnology cooperation consistent with the initiative on Critical and Emerging Technology (iCET) and beyond. Following these workshops, peer-reviewed workshop proceedings will be published.
Details of Dr. Musunuri’s panel are as follows:
Panel Discussion Title: Persistent Challenges: Right-Sizing Regulations and Setting Standards Beyond the Biomedical Sphere
Date: Tuesday, September 10, 2024
Time: 10:45 a.m.-noon IST
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When and where is Dr. Shankar Musunuri speaking at the U.S.-India biotechnology workshop?
What is the title of the panel discussion Dr. Musunuri is participating in?
What is the main focus of Ocugen (OCGN) as a biotechnology company?
How is Ocugen (OCGN) contributing to U.S.-India biotechnology cooperation?
Who are the organizers of the U.S.-India biotechnology cooperation workshop?
